Evolution of the Average Target: Ipsen

Evolution of the Target Price: Ipsen

Changes in Analyst Recommendations: Ipsen

0f9e2d.5SNe17HR-1rbdi2apvkYXkvOPmtHiObsfH_ca09csQg.oXNnudqjuQXtMETP_JRRcyGjBi1qvomdUR6wLjlr6UfIFxO7-Z-dHb4EGQ~d55cd27d51f19a6833dccecc51b66855
08-20 Cancer vaccines finally garner the spotlight Alphavalue
08-17 Kepler Cheuvreux Boosts Ipsen PT, Maintains Hold Rating MT
08-03 Jefferies Downgrades Ipsen to Underperform, Boosts PT MT
07-30 Ipsen: Another quarterly beat; 2026 guidance upgraded Alphavalue
07-14 Where would AI lead Pharma in the long run? Alphavalue
07-07 AlphaValue/Baader Europe Cuts Ipsen Price Target Amid Future Patent Expiries, Mid-term Risks MT
07-06 Ipsen: Reassessing mid-term risks Alphavalue
07-01 AlphaValue/Baader Europe Downgrades Ipsen to Add, Lifts PT MT
07-01 Oddo BHF still neutral on Ipsen after a new acquisition Zonebourse
06-30 Ipsen Extends Its Rally, Backed by Oddo BHF Zonebourse
06-05 HC Wainwright Starts Ipsen Coverage with Buy Rating MT
05-28 Ipsen Price Target, Estimates Up as AlphaValue/Baader Europe Notes Upcoming Data Readouts, Product Mix MT
05-27 Ipsen: Beneficiary of favourable product mix and imminent readouts Alphavalue
04-24 Profit-taking hits Ipsen despite UBS price target hike Zonebourse
04-23 Ipsen: Opened the year with encouraging traction Alphavalue
04-14 Deutsche Bank raises price target on Ipsen Zonebourse
03-16 BNP Paribas Upgrades Ipsen to Neutral, Boosts PT MT
03-10 CIC Corporate & Institutional Banking Upgrades Ipsen to Buy, Boosts PT MT
02-13 Ipsen Remains in the Green with UBS Support Zonebourse
02-12 Ipsen: Markets applaud strong finish to 2025 and better-than-expected 2026 outlook Alphavalue
01-14 Ipsen, Top Gainer on the SBF 120 and SRD at Wednesday, January 14, 2026 Close Zonebourse
01-14 Ipsen and EMS-Chemie Shine on the Stock Market, Vistry and Pearson Struggle Zonebourse
01-08 UBS No Longer Recommends Buying Ipsen, Citing Full Valuation Zonebourse
11-26 BNP Paribas Downgrades Ipsen to Underperform, Trims PT MT
11-18 AlphaValue/Baader Europe Ups Ipsen's EPS Forecasts After Q3 Beat, 'Substantial' FY25 Outlook Upgrade MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+11.96%
+1.66%
+8.26%
+3.24%
+0.76%
+31.03%
-10.16%
+4.82%
+8.05%
Average +6.62%
Weighted average by Cap. +7.26%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
163.10EUR
Average target price
167.07EUR
Spread / Average Target
+2.43%
High Price Target
235.00EUR
Spread / Highest target
+44.08%
Low Price Target
130.00EUR
Spread / Lowest Target
-20.29%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
AA